Diabetes, Healthy
Conditions
Brief summary
This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
Interventions
DRUGFurosemide
Oral administration A total of three single doses.
DRUGRosuvastatin
Oral administration. A total of three single doses.
DRUGSNAC
Oral administration. A total of five single doses.
DRUGSemaglutide
Oral administration. Once daily.
Sponsors
Novo Nordisk A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 20.0-29.9 kg/m\^2 (both inclusive) * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiography and clinical laboratory tests performed during the screening visit, as judged by the investigator
Exclusion criteria
* Smoker (defined as a subject who is smoking at least one cigarette or the equivalent per day) * Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening * History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) * Have personal or family history of myopathy * Previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate * Thyroid-Stimulating Hormone outside lower limit of normal minus 10 percent and upper limit of normal plus 10 percent * Creatine kinase above 5 x upper limit of normal * Asian subject
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the furosemide plasma concentration-time curve | day 1, day 7, day 54 | Based on sampling between 0 and 12 hours |
| Area under the rosuvastatin plasma concentration-time curve | day 2, day 8, day 55 | Based on sampling between 0 and 96 hours |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed furosemide plasma concentration | day 1, day 7, day 54 |
| Maximum observed rosuvastatin plasma concentration | day 2, day 8, day 55 |
Countries
United Kingdom
Outcome results
None listed